ArticleMicrobial cell factories2020
The generation of metabolic changes for the production of high-purity zeaxanthin mediated by CRISPR-Cas9 in Chlamydomonas reinhardtii.
Article in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 89 citations in OpenAlex.
- CRISPR-enhanced microalgae for carbon sequestration and carotenoid production: opportunities and fundamental constraints.Bioresources and bioprocessing · 2026Review
- Metabolic engineering strategies: utilizing different microbial strains and advanced technologies for the synthesis of high-valued terpenoids.Antonie van Leeuwenhoek · 2026Review
- Synthetic Biology and Metabolic Engineering of Microalgae for Sustainable Lipid and Terpenoid Production: An Updated Perspective.Plant biotechnology journal · 2026Review
- Microplastic Pollution: Advancements in Mitigation, Policy Challenges, and Future Directions.Current microbiology · 2026Review
- Enhancement of growth and zeaxanthin accumulation via gene expression and metabolic pathways modulation in Chromochloris zofingiensis mutant CZ-Z12.Biotechnology for biofuels and bioproducts · 2026Article
- CRISPR-Cas Technology TurnsMarine drugs · 2025Review
- Transcriptional gene fusions via targeted integration at safe harbors for high transgene expression in Chlamydomonas reinhardtii.The New phytologist · 2025Article
- High-yield zeaxanthin production in Chlamydomonas reinhardtii via advanced metabolic pathway engineering.Biotechnology for biofuels and bioproducts · 2025Article
- EngineeredLife (Basel, Switzerland) · 2025Article
- Review
- Progress and challenges in CRISPR/Cas applications in microalgae.Journal of microbiology (Seoul, Korea) · 2025Review
- Charting the state of GEMs in microalgae: progress, challenges, and innovations.Frontiers in plant science · 2025Review
- Genetic Engineering and Innovative Cultivation Strategies for Enhancing the Lutein Production in Microalgae.Marine drugs · 2024Review
- CRISPR/Cas9-Mediated Knockout of the Lycopene ε-Cyclase for Efficient Astaxanthin Production in the Green MicroalgaPlants (Basel, Switzerland) · 2024Article
- Photoautotrophic cultivation of a Chlamydomonas reinhardtii mutant with zeaxanthin as the sole xanthophyll.Biotechnology for biofuels and bioproducts · 2024Article
- Microalgae: towards human health from urban areas to space missions.Frontiers in plant science · 2024Article
- Promoting Photosynthetic Production of Dammarenediol-II inInternational journal of molecular sciences · 2023Article
- Zeaxanthin epoxidase is involved in the carotenoid biosynthesis and light-dependent growth of the marine alga Nannochloropsis oceanica.Biotechnology for biofuels and bioproducts · 2023Article
- Review
- CRISPR-based bioengineering in microalgae for production of industrially important biomolecules.Frontiers in bioengineering and biotechnology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundZeaxanthin, a major xanthophyll pigment, has a significant role as a retinal pigment and antioxidant. Because zeaxanthin helps to prevent age-related macular degeneration, its commercial use in personalized nutritional and pharmaceutical applications has expanded. To meet the quantitative requirements for personalized treatment and pharmaceutical applications, it is necessary to produce highly purified zeaxanthin.
resultsIn this study, to meet the quantitative requirements for industrial applications, we generated a double knockout mutant which is gene-edited by the CRISPR-Cas9 ribonucleoprotein-mediated knock-in system. The lycopene epsilon cyclase (LCYE) was edited to the elimination of α-branch of xanthophyll biosynthesis in a knockout mutant of the zeaxanthin epoxidase gene (ZEP). The double knockout mutant (dzl) had a 60% higher zeaxanthin yield (5.24 mg L
conclusionsA Chlamydomonas strain with the elimination of lutein production by gene editing using CRISPR-Cas9 has been successfully developed. This research presents a solution to overcome the difficulties of the downstream-process for the production of high-purity zeaxanthin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.